

## Special Issue

# Drug Candidates for the Treatment of Genitourinary Malignancies

### Message from the Guest Editors

Genitourinary malignancies include some of the most prevalent types of cancer worldwide, such as prostate, uterine, cervix and bladder cancer, as well as less prevalent lesions, including vulvar, vaginal and penile cancers. The varied etiology and the molecular heterogeneity of genitourinary cancers represent major challenges for cancer therapy. .... This Special Issue aims to highlight timely studies of innovative drug candidates for genitourinary cancers and their molecular targets, including pre-clinical and clinical studies, as well as review articles. Translational research studies are particularly welcome. Studies that deal with the molecular heterogeneity of genitourinary cancers and approaches to therapeutically target specific tumor subsets are also of particular interest. Finally, this Special Issue also aims to showcase studies that deal with less-studied cancers with higher incidence in developing countries, such as penile cancer.

### Guest Editors

Dr. Rui M. Gil da Costa

1. Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal
2. Post-Graduate Programme in Adult Health (PPGSAD), Federal University of Maranhão, São Luís 65085-580, Brazil
3. Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production (Inov4Agro), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal

Dr. Haissa Oliveira Brito

Post-Graduate Programme in Adult Health, Universidade Federal do Maranhão, São Luís, Brazil

### Deadline for manuscript submissions

closed (15 September 2022)



## Pharmaceuticals

an Open Access Journal  
by MDPI

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/117443](https://mdpi.com/si/117443)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)